ES2678144T3 - Composiciones relacionadas con SAH y métodos de uso - Google Patents
Composiciones relacionadas con SAH y métodos de uso Download PDFInfo
- Publication number
- ES2678144T3 ES2678144T3 ES11745103T ES11745103T ES2678144T3 ES 2678144 T3 ES2678144 T3 ES 2678144T3 ES 11745103 T ES11745103 T ES 11745103T ES 11745103 T ES11745103 T ES 11745103T ES 2678144 T3 ES2678144 T3 ES 2678144T3
- Authority
- ES
- Spain
- Prior art keywords
- remainder
- sah
- residue
- amino acid
- acid substitutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un polipéptido que comprende una parte de seroalbúmina humana (SAH), cuya parte de SAH comprende el dominio III de SAH o un fragmento de unión al receptor Fc neonatal (FcRn) del mismo, en el que: el dominio III de SAH comprende una o más sustituciones de aminoácido en cualquiera de las siguientes posiciones, numeradas respecto a la posición en la SAH madura de longitud completa (SEQ ID NO: 2): resto 407, resto 415, resto 424, resto 426, resto 463, resto 506, resto 508, resto 509, resto 511, resto 512, resto 515, resto 521, resto 523, resto 524, resto 526, resto 535 y resto 557; la una o más sustituciones de aminoácido aumentan una o ambas de la afinidad por FcRn y semivida en suero del polipéptido respecto a un polipéptido de control en que la parte de SAH no incluye dichas sustituciones de aminoácido; y en el que, las sustituciones de aminoácido en la posición 506 se seleccionan de T506F, T506W, T506Y; las sustituciones de aminoácido en la posición 508 se seleccionan de T508K, T508R, T508S; y las sustituciones de aminoácido en la posición 535 se seleccionan de H535D, H535E, H535P.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30495410P | 2010-02-16 | 2010-02-16 | |
US36450310P | 2010-07-15 | 2010-07-15 | |
PCT/US2011/024855 WO2011103076A1 (en) | 2010-02-16 | 2011-02-15 | Hsa-related compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2678144T3 true ES2678144T3 (es) | 2018-08-09 |
Family
ID=44483259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11745103T Active ES2678144T3 (es) | 2010-02-16 | 2011-02-15 | Composiciones relacionadas con SAH y métodos de uso |
Country Status (9)
Country | Link |
---|---|
US (2) | US8697650B2 (es) |
EP (1) | EP2536756B1 (es) |
JP (1) | JP2013519392A (es) |
KR (1) | KR20130020765A (es) |
CN (2) | CN102781960B (es) |
AU (1) | AU2011218294A1 (es) |
CA (1) | CA2789337A1 (es) |
ES (1) | ES2678144T3 (es) |
WO (1) | WO2011103076A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG2014012918A (en) | 2009-02-11 | 2014-04-28 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
JP2014510518A (ja) * | 2011-02-15 | 2014-05-01 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
CN104011072B (zh) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
SI2771022T1 (sl) | 2011-10-11 | 2020-12-31 | Viela Bio, Inc. | CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe |
US20140315817A1 (en) * | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
PL2825556T3 (pl) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Warianty albuminy |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
CN105007722A (zh) * | 2013-02-16 | 2015-10-28 | 诺维信生物制药丹麦公司 | 药代动力学动物模型 |
WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
LT3007717T (lt) * | 2013-06-12 | 2018-11-26 | Pharis Biotec Gmbh | Peptidai su antagonistiniu veikimu prieš gamtinį cxcr4 |
EP3063171B1 (en) * | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
US9518118B2 (en) | 2014-09-12 | 2016-12-13 | Genentech, Inc. | Anti-HER2 antibodies and immunoconjugates |
KR20170055521A (ko) | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | 항-her2 항체를 포함하는 면역콘주게이트 |
JP6862348B2 (ja) | 2015-03-12 | 2021-04-21 | メディミューン,エルエルシー | アルブミン融合タンパク質を精製する方法 |
CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
WO2017112549A1 (en) | 2015-12-23 | 2017-06-29 | Biogen Ma Inc. | Dkk2 cysteine rich domain 2 containing proteins and uses thereof |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
WO2018082758A1 (en) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
AU2018288854A1 (en) | 2017-06-20 | 2019-11-21 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists |
CA3064037A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
US11466073B2 (en) | 2017-10-18 | 2022-10-11 | Csl Limited | Human serum albumin variants and uses thereof |
KR20200093562A (ko) | 2017-11-29 | 2020-08-05 | 씨에스엘 리미티드 | 허혈-재관류 손상을 치료 또는 예방하는 방법 |
CN111712231A (zh) * | 2018-02-23 | 2020-09-25 | 百多力股份公司 | 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法 |
KR20210013091A (ko) | 2018-05-16 | 2021-02-03 | 시에스엘 리미티드 | 가용성 보체 수용체 1형 변이체 및 이의 용도 |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
WO2020051331A1 (en) * | 2018-09-07 | 2020-03-12 | Medimmune, Llc | Methods of cell selection |
KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
CR20220096A (es) | 2019-09-06 | 2022-05-11 | Novartis Ag | Proteínas de fusión terapéuticas |
WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
WO2024089258A1 (en) | 2022-10-28 | 2024-05-02 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
WO2003059934A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060051859A1 (en) | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
JP2009511067A (ja) | 2005-10-14 | 2009-03-19 | メディミューン,エルエルシー | 抗体ライブラリーの細胞提示 |
JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
SG2014012918A (en) | 2009-02-11 | 2014-04-28 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
JP5841046B2 (ja) * | 2009-04-08 | 2016-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 制御された血清中薬物動態を有するヒトタンパク質スキャフォールド |
US20110015130A1 (en) | 2009-07-20 | 2011-01-20 | Woei-Jer Chuang | Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
RU2607374C2 (ru) * | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
GB2476671B (en) | 2010-01-04 | 2014-11-26 | Plastic Logic Ltd | Touch-sensing systems |
JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
ES2674567T3 (es) | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
JP5240316B2 (ja) | 2010-10-26 | 2013-07-17 | 株式会社デンソー | 車両乗員非操作運転システム |
US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
JP2014510518A (ja) | 2011-02-15 | 2014-05-01 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
KR20140035357A (ko) | 2011-04-05 | 2014-03-21 | 셰브런 오로나이트 컴퍼니 엘엘씨 | 저점도 선박 실린더 윤활유 조성물 |
CN104011072B (zh) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
-
2011
- 2011-02-15 JP JP2012553964A patent/JP2013519392A/ja active Pending
- 2011-02-15 US US13/578,688 patent/US8697650B2/en active Active
- 2011-02-15 WO PCT/US2011/024855 patent/WO2011103076A1/en active Application Filing
- 2011-02-15 CN CN201180012375.4A patent/CN102781960B/zh not_active Expired - Fee Related
- 2011-02-15 KR KR1020127022893A patent/KR20130020765A/ko not_active Application Discontinuation
- 2011-02-15 ES ES11745103T patent/ES2678144T3/es active Active
- 2011-02-15 AU AU2011218294A patent/AU2011218294A1/en not_active Abandoned
- 2011-02-15 CN CN201410635751.0A patent/CN104610454A/zh active Pending
- 2011-02-15 CA CA2789337A patent/CA2789337A1/en not_active Abandoned
- 2011-02-15 EP EP11745103.9A patent/EP2536756B1/en active Active
-
2014
- 2014-02-14 US US14/181,339 patent/US9120875B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2536756A4 (en) | 2013-08-14 |
US20140248682A1 (en) | 2014-09-04 |
CA2789337A1 (en) | 2011-08-25 |
JP2013519392A (ja) | 2013-05-30 |
EP2536756A1 (en) | 2012-12-26 |
US8697650B2 (en) | 2014-04-15 |
CN102781960A (zh) | 2012-11-14 |
EP2536756B1 (en) | 2018-04-25 |
US9120875B2 (en) | 2015-09-01 |
WO2011103076A1 (en) | 2011-08-25 |
US20130053322A1 (en) | 2013-02-28 |
KR20130020765A (ko) | 2013-02-28 |
AU2011218294A1 (en) | 2012-08-30 |
CN102781960B (zh) | 2014-12-10 |
CN104610454A (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2678144T3 (es) | Composiciones relacionadas con SAH y métodos de uso | |
CY1124525T1 (el) | Προσδετες τροποποιημενοι με κυκλικη μεταθεση ως αγωνιστες και ανταγωνιστες | |
PH12018501250A1 (en) | Chimeric factor viii polypeptides and uses thereof | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
BR112015024587A2 (pt) | variante de região fc | |
BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
NZ722055A (en) | Fcrn antagonists and methods of use | |
EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
BR112013026828A2 (pt) | polipeptídeos de anticorpo que antagonizam cd40 | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
NZ606584A (en) | Binding proteins for hepcidin | |
CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
GB201009493D0 (en) | Modified recombinant factor viii and von willebrand factor and methods of use | |
NZ592611A (en) | A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
NZ602634A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
EA201170879A1 (ru) | Полипептиды с ксиланазной активностью | |
UA108778C2 (xx) | Протираковий злитий протеїн | |
MX2017007303A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
PL397595A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου |